|
Abaloparatide
|
Tymlos |
BA058|BA-058|BIM44058|BIM-44058 |
|
Abaloparatide (Tymlos) is a peptide analog of human parathyroid hormone-related protein (PTHrP), which stimulates bone formation and potentially increases bone mineral density (PMID: 25393645, PMID: 29260289). Abaloparatide (Tymlos) is FDA approved for osteoporosis (FDA.gov). |
|
Adagrasib
|
Krazati |
MRTX849|MRTX-849|MRTX 849 |
KRAS G12C inhibitor
34
|
Krazati (adagrasib) covalently binds to and stabilizes GDP-bound KRAS G12C, thereby preventing KRAS downstream signaling and potentially inhibiting tumor growth (PMID: 31658955). Krazati (adagrasib) is FDA-approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy, and in combination with Erbitux (cetuximab) for patients with advanced or metastatic colorectal cancer harboring KRAS G12C (FDA.gov). |
|
Amivantamab-vmjw
|
Rybrevant |
JNJ-61186372 |
EGFR Antibody
60
MET Antibody
31
|
Rybrevant (amivantamab-vmjw) is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193, PMID: 32414908). Rybrevant (amivantamab-vmjw) is FDA-approved for use in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, in combination with carboplatin and pemetrexed as first-line therapy for adult patients with NSCLC harboring EGFR exon 20 insertion mutations and for patients harboring EGFR exon 19 deletion or L858R who progressed on prior EGFR TKI, and in combination with Lazcluze (lazertinib) as first-line therapy in patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov). |
|
Apalutamide
|
Erleada |
ARN-509|JNJ-56021927 |
Hormone - Anti-androgens
54
|
Erleada (apalutamide) is a second-generation antiandgrogen, that binds to the androgen receptor (AR) and inhibits downstream signaling, potentially resulting in decreased growth of AR-expressing tumors (PMID: 22266222, PMID: 23337756). Erleada (apalutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (FDA.gov). |
|
Asciminib
|
Scemblix |
ABL001|ABL-001 |
BCR-ABL Inhibitor
32
|
Scemblix (asciminib) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (PMID: 31543464, PMID: 31826340). Scemblix (asciminib) is FDA approved for use in patients with newly-diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), and in Ph+ CML patients in CP after two or more tyrosine kinase inhibitor treatments, and in adult patients with Ph+ CML in CP harboring ABL1 T315I (FDA.gov). |
|
Asparaginase Erwinia chrysanthemi
|
Erwinaze |
Crisantaspase |
|
Erwinaze (asparaginase Erwinia chrysanthemi) is an bacterial derived enzyme that converts L-asparagine to L-aspartate and ammonia, which decreases L-asparagine levels, potentially leading to reduced leukemic cell growth (PMID: 25098829, PMID: 26698391). Erwinaze (asparaginase Erwinia chrysanthemi) is FDA-approved for use in a chemotherapeutic regimen for acute lymphoblastic leukemia (FDA.gov). |
|
Atezolizumab
|
Tecentriq |
RG7446|MPDL3280A |
Immune Checkpoint Inhibitor
149
PD-L1/PD-1 antibody
121
|
Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>/=50% or IC>/=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov). |
|
Axatilimab
|
Niktimvo |
SNDX 6352|SNDX6352|UCB6352|SNDX-6352 |
CSF1R Antibody
5
|
Niktimvo (axatilimab) is a humanized monoclonal antibody against colony-stimulating factor-1 receptor (CSF-1R), which may enhance anti-tumor immune response (SITC Meeting, Nov 2017, abstract P505). Niktimvo (axatilimab) is FDA-approved for the treatment of chronic graft-versus-host disease (FDA.gov) |
|
BCG solution
|
TICE BCG solution |
Bacillus Calmette-Guerin solution |
|
TICE BCG solution (BCG solution) is an attenuated live culture of Bacillus Calmette Guerin that induces anti-tumor immunity in bladder cancer (PMID: 26000263). TICE BCG solution (BCG solution) is FDA approved for carcinoma in situ of the bladder (FDA.gov). |
|
Balsalazide
|
Carbadox |
Balsalazida |
|
Carbadox (balsalazide) is a 5-aminosalicylate (5-ASA) type drug that is FDA approved for the treatment of inflammation resulting from ulcerative colitis (FDA.gov), however, has also been demonstrated to induce apoptosis and decrease cell proliferation in cancer cells (PMID: 28108625). |
|
Belzutifan
|
Welireg |
PT2977|MK-6482|PT-2977 |
HIF2A Inhibitor
6
|
Welireg (belzutifan) is a hypoxia inducible factor-2alpha (EPAS1, HIF2A) inhibitor that suppresses expression of HIF2A target genes, resulting in tumor regression (Mol Cancer Ther 2018,17(1 Suppl):Abstract nr B140, PMID: 31282155). Welireg (belzutifan) is FDA-approved for use in patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that require therapy, and in patients with advanced renal cell carcinoma who have received anti-PD-1 or PD-L1 therapy and VEGF inhibitor (FDA.gov). |
|
Brexucabtagene autoleucel
|
Tecartus |
KTE-X19|KTEX19|KTE X19 |
|
Tecartus (brexucabtagene autoleucel) are autologous T-cells engineered to express an anti-CD-19 chimeric antigen receptor (CAR), which may potentially target CD-19-expressing tumor cells (PMID: 32242358). Tecartus (brexucabtagene autoleucel) is FDA approved for use in adult patients with relapsed or refractory mantle cell lymphoma and patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov). |
|
Capivasertib
|
Truqap |
AZD5363|AZD 5363|AZD-5363 |
Akt Inhibitor (Pan)
21
|
Truqap (capivasertib) decreases PI3K/AKT/mTOR signaling by inhibition of AKT1, AKT2, and AKT3, potentially resulting in decreased cell proliferation (PMID: 22294718, PMID: 32532747, PMID: 32312891). Truqap (capivasertib) in combination with Faslodex (fulvestrant) is FDA-approved for use in patients with hormone receptor-positive, ERBB2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations (FDA.gov). |
|
Capmatinib
|
Tabrecta |
INC280|INC-280|INCB028060|INCB28060|INCB 28060 |
MET Inhibitor
59
|
Tabrecta (capmatinib) inhibits MET signaling and may induce cell death in tumors overexpressing MET or expressing constitutively activated MET (PMID: 31853265). Tabrecta (capmatinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
|
Carfilzomib
|
Kyprolis |
PR-171 |
|
Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells (PMID: 26893241). Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone, or in combination with Darzalex Faspro (Daratumumab and hyaluronidase-fihj) and dexamethasone is FDA-approved for use in patients with multiple myeloma (FDA.gov). |
|
Celecoxib
|
|
|
|
Celecoxib is a COX-2 inhibitor that blocks inflammatory response and has anti-angiogenic and anti-proliferative activities (PMID: 31726219), which may lead to tumor growth inhibition (PMID: 17909047, PMID: 16740761). |
|
Cyclophosphamide
|
Cytoxan |
CPM |
Chemotherapy - Alkylating
18
|
Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
|
Dabrafenib
|
Tafinlar |
GSK2118436 |
BRAF Inhibitor
25
|
Tafinlar (dabrafenib) inhibits the activity of BRAF, including V600E, which results in the inhibition of tumor cell proliferation (PMID: 22735384). Tafinlar (dabrafenib) is FDA approved for BRAF V600E/K- positive unresectable or metastatic melanoma, and in combination with Mekinist (trametinib) for BRAF V600E/K-mutant melanoma, BRAF V600E-mutant non-small cell lung cancer, BRAF V600E-mutant anaplastic thyroid cancer, for adult and pediatric patients of 6 years or older with unresectable or metastatic solid tumors harboring BRAF V600E, and for pediatric patients of 1 year or older with low-grade glioma harboring BRAF V600E (FDA.gov). |
|
Dacarbazine
|
Deticene |
Biocarbazine R |
Chemotherapy - Alkylating
18
|
Deticene (dacarbazine) alkylates and cross-links DNA, which disrupts the cell-cycle. Dacarbazine is FDA approved for melanoma (FDA.gov). |
|
Daratumumab
|
Darzalex |
JNJ-54767414 |
CD38 Antibody
20
|
Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov). |
|
Daratumumab and hyaluronidase-fihj
|
Darzalex Faspro |
Daratumumab/rHuPH20|HuMax-CD38-rHuPH20|darzalex/rHuPH20 |
CD38 Antibody
20
|
Darzalex Faspro (Daratumumab and hyaluronidase-fihj) is a combination of the anti-CD38 antibody Daratumumab with hyaluronidase, which may be administered subcutaneously (PMID: 32213342). Darzalex Faspro (Daratumumab and hyaluronidase-fihj) is FDA approved as a monotherapy or in combination with lenalidomide and dexamethasone, or with pomalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with Kyprolis (carfilzomib) and dexamethasone, or with bortezomib, lenalidomide, and dexamethasone for patients with multiple myeloma, and in combination with bortezomib, cyclophosphamide and dexamethasone in patients with newly diagnosed light chain amyloidosis (FDA.gov). |
|
Darbepoetin Alfa
|
Aranesp |
NESP|Nespo|Novel Erythropoiesis Stimulating Protein |
|
Aranesp (darbepoetin alfa) is a recombinant analog of erythropoietin, which upon binding to the erythropoietin receptor, induces differentiation of erythroid progenitor cells into mature red blood cells (PMID: 16333460). Aranesp (darbepoetin alfa) is approved for the treatment of anemia in patients with cancer and chronic kidney disease (FDA.gov). |
|
Darolutamide
|
Nubeqa |
BAY1841788|ODM-201 |
Hormone - Anti-androgens
54
|
Nubeqa (darolutamide) is an androgen receptor antagonist that binds to and prevents nuclear translocation of the androgen receptor, thereby inhibiting expression of genes downstream of androgen receptor signaling that regulate proliferation of prostate cancer cells (PMID: 28490267). Nubeqa (darolutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer, and in combination with docetaxel in patients with metastatic hormone-sensitive prostate cancer (FDA.gov). |
|
Daunorubicin
|
Cerubidine |
Rubidomycin|daunomycin hydrochloride|rubomycin C|Acetyladriamycin |
Chemotherapy - Anthracycline
13
|
Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair. Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov). |
|
Daunoxome
|
|
Liposomal daunorubicin citrate |
Chemotherapy - Anthracycline
13
|
Daunoxome is a liposomal formulation of the anthracyline, daunorubicin and is FDA approved for HIV-associated Kaposi’s sarcoma (FDA.gov). |
|
Decitabine and Cedazuridine
|
Inqovi |
ASTX-727|ASTX 727|ASTX727 |
Chemotherapy - Antimetabolite
14
|
Inqovi (decitabine and cedazuridine) is a combination of decitabine and cedazuridine, which may inhibit proliferation of tumor cells (PMID: 30926081). Inqovi (decitabine and cedazuridine) is an FDA approved chemotherapy agent (FDA.gov). |
|
Deucravacitinib
|
Sotyktu |
BMS986165|BMS-986165|BMS 986165 |
|
Sotyktu (deucravacitinib) is a selective allosteric TYK2 inhibitor that potentially inhibits tumor cell proliferation (PMID: 36799629). Sotyktu (deucravacitinib) is FDA-approved for use in patients with plaque psoriasis (FDA.gov). |
|
Divalproex sodium
|
Depakote |
Valproate semisodium|Sodium divalproex |
HDAC Inhibitor
45
|
Depakote (Divalproex sodium) comprises a 1:1 mixture of valproic acid and sodium valproate, which acts as an HDAC inhibitor, potentially resulting in decreased growth and increased apoptosis of tumor cells in combination with other agents (PMID: 25449787, PMID: 20200483). Depakote (divalproex sodium) is FDA approved for treatment of manic episodes associated with bipolar disorder, as well as seizures, and migraines (FDA.gov). |
|
Dostarlimab-gxly
|
Jemperli |
TSR-042 |
Immune Checkpoint Inhibitor
149
PD-L1/PD-1 antibody
121
|
Jemperli (dostarlimab-gxly) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 34313545). Jemperli (dostarlimab-gxly) is FDA approved for use in patients with recurrent or advanced endometrial cancer or solid tumors harboring mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have progressed on prior treatments, and in combination with Paraplatin (carboplatin) and Taxol (paclitaxel), followed by Jemperli (dostarlimab-gxly) monotherapy, in patients with primary advanced or recurrent endometrial cancer (FDA.gov). |
|
Doxorubicin
|
Adriamycin |
Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin |
Chemotherapy - Anthracycline
13
TOPO2 inhibitor
5
|
Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
|
Duvelisib
|
Copiktra |
IPI-145|INK1197 |
PIK3CD inhibitor
27
PIK3CG inhibitor
10
|
Copiktra (duvelisib) prevents the activation of the PI3K delta/gamma-mediated signaling pathways, resulting in tumor cell death (PMID: 25258342). Copiktra (duvelisib) is FDA approved for use in adult patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma (FDA.gov) |
|
Eflornithine
|
Iwilfin |
DFMO|alpha-difluoromethylornithine |
|
Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor that blocks polyamine production, resulting in reduced tumor cell proliferation (PMID: 32256343). Iwilfin (eflornithine) is FDA-approved for use in adult and pediatric patients with high-risk neuroblastoma who have responded to prior therapies (FDA.gov) |
|
Elacestrant
|
Orserdu |
RAD1901 |
Hormone - Anti-estrogens
29
|
Orserdu (elacestrant) is a selective estrogen receptor degrader that down-regulates ER and ER-regulated genes, resulting in anti-tumor activity and may be effective in cells resistant to CDK4/6 inhibitors (PMID: 28473534, PMID: 31852484). Orserdu (elacestrant) is FDA approved for use in postmenopausal women or adult men with ER-positive, ERBB2 (HER2)-negative, ESR1 (ER alpha)-mutated advanced or metastatic breast cancer progressed on endocrine therapy (FDA.gov). |
|
Elranatamab-bcmm
|
Elrexfio |
PF-06863135|PF06863135|PF 06863135 |
CD3 Antibody
99
TNFRSF17 Antibody
20
|
Elrexfio (elranatamab-bcmm) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). Elrexfio (elranatamab-bcmm) is FDA -approved for use in patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (FDA.gov). |
|
Enfortumab vedotin-ejfv
|
Padcev |
AGS-22ME|Enfortumab vedotin|AGS-22M6E|ASG-22CE |
|
Padcev (enfortumab vedotin-ejfv) is an antibody-drug conjugate (ADC) that fuses together a human antibody against NECTIN4 and monomethyl auristatin E, which may result in inhibition of tumor growth and tumor regression (PMID: 27013195). Padcev (enfortumab vedotin-ejfv) is FDA approved for use in patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy, and in combination with Keytruda (pembrolizumab) for patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy (FDA.gov). |
|
Entrectinib
|
Rozlytrek |
RXDX-101 |
ALK Inhibitor
32
ROS1 Inhibitor
20
Trk Receptor Inhibitor (Pan)
32
|
Rozlytrek (entrectinib) inhibits the activity of TrkA/B/C, Ros1 fusion proteins, and Alk, which leads to induction of apoptosis and inhibition of proliferation in cells expressing these kinases (PMID: 27003761). Rozlytrek (entrectinib) is FDA approved for use in patients with ROS1 positive non-small cell lung cancer and in adult and pediatric (1 year and older) patients with solid tumors harboring NTRK fusions without known acquired resistance mutations (FDA.gov). |
|
Epcoritamab-bysp
|
Epkinly |
DuoBody-CD3xCD20|GEN 3013|GEN-3013|GEN3013|epcoritamab |
CD20 Antibody
24
CD3 Antibody
99
|
Epkinly (epcoritamab-bysp) is a bispecific antibody that targets CD3 and CD20, resulting in T-cell activation and redirection of T-cells to CD20-expressing tumor cells, which may lead to tumor cell cytotoxicity and inhibition of tumor growth (PMID: 31981978, PMID: 33602901). Epkinly (epcoritamab-bysp) is FDA-approved for use in patients with relapsed or refractory diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma after two or more lines of systemic therapy (FDA.gov). |
|
Epirubicin
|
Ellence |
Epirubicin Hydrochloride |
Chemotherapy - Anthracycline
13
|
Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov). |
|
Erlotinib
|
Tarceva |
CP358774 |
EGFR Inhibitor (Pan)
62
EGFR Inhibitor 1st gen
3
|
Tarceva (erlotinib) is a first-generation EGFR inhibitor that blocks EGFR signaling, potentially leading to inhibition of tumor growth (PMID: 30069756). Tarceva (erlotinib) is FDA approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions and/or EGFR L858R, and in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic pancreatic cancer (FDA.gov). |
|
Fedratinib
|
Inrebic |
SAR302503|TG101348 |
FLT3 Inhibitor
69
JAK2 Inhibitor - ATP competitive
15
RET Inhibitor
53
|
Inrebic (fedratinib) binds and inhibits JAK2, FLT3, and RET kinases, which may inhibit cell proliferation and tumor growth (PMID: 17541402). Inrebic (fedratinib) is FDA approved for use in patients with myelofibrosis (FDA.gov). |
|
Fluorouracil
|
Adrucil |
5-FU|5-Fluorouracil |
Chemotherapy - Antimetabolite
14
|
Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov). |
|
Fruquintinib
|
Fruzaqla |
HMPL-013 |
VEGFR Inhibitor (Pan)
36
|
Fruzaqla (fruquintinib) binds and inhibits VEGFR1/2/3, potentially resulting in reduced cell proliferation and decreased tumor growth (PMID: 25482937, PMID: 31790382). Fruzaqla (fruquintinib) is FDA approved for use in patients with metastatic colorectal cancer who have received prior therapy (FDA.gov). |
|
Fulvestrant
|
Faslodex |
ICI 182,780 |
Hormone - Anti-estrogens
29
|
Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
|
Futibatinib
|
Lytgobi |
TAS-120 |
FGFR Inhibitor (Pan)
26
|
Lytgobi (futibatinib) is a third-generation pan-FGFR inhibitor, which results in the inhibition of FGFR-mediated signal transduction pathways and tumor cell proliferation (PMID: 31109923). Lytgobi (futibatinib) is FDA approved for use in patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (FDA.gov). |
|
Glofitamab-gxbm
|
Columvi |
RO 7082859|RO-7082859|RO7082859 |
CD20 Antibody
24
CD3 Antibody
99
|
Columvi (glofitamab-gxbm) is a bispecific antibody that binds the tumor-associated antigen, MS4A1 (CD20), and CD3 on T-cells to stimulate T-cell killing of CD20-expressing tumor cells (PMID: 36507690). Columvi (glofitamab-gxbm) is FDA-approved for use in patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy (FDA.gov). |
|
Goserelin
|
Zoladex |
Goserelin acetate |
|
Zoladex (goserelin) is a synthetic analog of lutenizing hormone-releasing hormone, which causes decreased testosterone production in males and decreased estradiol production in females, and is FDA approved for use in prostate carcinoma (FDA.gov). |
|
Ibritumomab tiuxetan
|
Zevalin |
IDEC Y2B8 |
CD20 Antibody
24
|
Zevalin (ibritumomab tiuxetan) is Yttrium-90 combined with the anti-CD20 antibody, rituximab, which may deliver radiation to tumor cells (PMID: 27497027). Zevalin (britumomab tiuxetan) is FDA approved for use in patients with low-grade or follicular B-cell non-Hodgkin's lymphoma (FDA.gov). |
|
Idarubicin
|
Idamycin |
Idarubicin Hcl |
Chemotherapy - Anthracycline
13
|
Idamycin (idarubicin) is an anthracycline that inhibits DNA replication thereby preventing RNA and protein synthesis, which may lead to tumor growth inhibition (PMID: 2192943). Idamycin (idarubicin) in combination with other approved drugs is FDA-approved for acute myelogenous leukemia (FDA.gov). |
|
Idecabtagene Vicleucel
|
Abecma |
Ide-cel|bb2121|BMS-986395 |
|
Abecma (idecabtagene vicleucel) is a chimeric antigen receptor T cell specific to B cell maturation antigen (BCMA), which could potentially result in decreased volume of BCMA expressing tumor cells (PMID: 32707894, PMID: 33626253). Abecma (idecabtagene vicleucel) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy (FDA.gov). |
|
Imetelstat
|
Rytelo |
GRN163L|JNJ-63935937|GRN 163L |
|
Rytelo (imetelstat) inhibits telomerase activity, resulting in telomere shortening and potentially leading to increased tumor cell death (PMID: 20048334, PMID: 32571117). Rytelo (imetelstat) is FDA-approved for use in patients with myelodysplastic syndromes with transfusion-dependent anemia (FDA.gov). |
|
Inavolisib
|
Itovebi |
GDC-0077|RO7113755|RG6114|GDC0077|GDC 0077 |
PIK3CA inhibitor
24
|
Itovebi (inavolisib) inhibits PIK3CA, with selectivity for mutant PIK3CA over wild-type PIK3CA, potentially resulting in increased apoptosis and decreased growth of PIK3CA-mutant tumors (PMID: 36455032). Itovebi (inavolisib) in combination with Ibrance (palbociclib) and Faslodex (fulvestrant) is FDA-approved for use in patients with endocrine-resistant, hormone receptor (HR)-positive, ERBB2 (HER2)-negative, locally advanced or metastatic breast cancer harboring PIK3CA mutations (FDA.gov). |
|
Infigratinib
|
Truseltiq |
BGJ398|BGJ-398|BGJ 398 |
FGFR Inhibitor (Pan)
26
|
Truseltiq (infigratinib) is a pan-FGFR inhibitor, which inhibits tumor angiogenesis and tumor cell proliferation (PMID: 31109923, PMID: 30101387). Truseltiq (infigratinib) is FDA approved for use in patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (FDA.gov). |
|
Isatuximab
|
Sarclisa |
SAR650984|isatuximab-irfc |
CD38 Antibody
20
|
Sarclisa (isatuximab-irfc) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056). Sarclisa (isatuximab-irfc) in combination with Pomalyst (pomalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received two or more prior therapies, in combination with Kyprolis (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, and in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone for patients with newly diagnosed multiple myeloma ineligible for transplant (FDA.gov). |
|
Lazertinib
|
Lazcluze |
GNS 1480|YH25448|JNJ-73841937|JNJ73841937|JNJ 73841937|YH 25448|YH-25448 |
EGFR Inhibitor 3rd gen
26
|
Lazcluze (lazertinib) is an irreversible protein kinase inhibitor with selective activity against mutant EGFR, which may lead to growth inhibition of EGFR-mutant tumor cells and reduced toxicity (PMID: 30670498, PMID: 32599977). Lazcluze (lazertinib) is FDA approved in combination with Rybrevant (amivantamab-vmjw) as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov) |
|
Letrozole
|
Femara |
Letrozol |
Aromatase Inhibitor
3
|
Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). |
|
Lifileucel
|
Amtagvi |
LN-144|LN144|LN 144 |
|
Amtagvi (lifileucel) is a preparation of tumor-infiltrating lymphocytes isolated and expanded from patient tumor tissue, which may demonstrate enhanced anti-tumor immune activity when re-introduced into patients (PMID: 33979178). Amtagvi (lifileucel) is FDA-approved for use in patients with previously treated unresectable or metastatic melanoma (FDA.gov). |
|
Liposomal irinotecan
|
Onivyde |
PEP02|nal-IRI|MM-398|Irinotecan Sucrosofate |
TOPO1 inhibitor
11
|
Onivyde (liposomal irinotecan) comprises irinotecan encapsulated in liposomal nanoparticles, which may result in increased tumor growth inhibition (PMID: 23406728, PMID: 16540680, PMID: 29945562). Onivyde (liposomal irinotecan) in combination with chemotherapy is FDA-approved for use in patients with metastatic pancreatic adenocarcinoma (FDA.gov). |
|
Lisocabtagene maraleucel
|
Breyanzi |
JCAR 017|JCAR017|JCAR-017 |
CD19 Immune Cell Therapy
62
|
Breyanzi (lisocabtagene maraleucel) comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may result in immune-modulating and anti-tumor activities (PMID: 32888407). Breyanzi (lisocabtagene maraleucel) is FDA approved for use in patients with large B-cell lymphoma including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who are refractory to or relapsed within 12 months of first-line immunochemotherapy, or have refractory or relapsed disease after first-line immunochemotherapy and not eligible for hematopoietic stem cell transplantation, or have relapsed or refractory disease after two or more lines of systemic therapy, and in patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy (FDA.gov). |
|
Loncastuximab tesirine-lpyl
|
Zynlonta |
ADCT-402 |
CD19 Antibody
21
|
Zynlonta (loncastuximab tesirine-lpyl) is a human anti-CD19 antibody in conjugation with a pyrrolobenzodiazepine (PBD) dimer toxin, which may specifically target CD19-positive tumor cells (Blood 2017 130(Suppl 1):187, PMID: 32012214). Zynlonta (loncastuximab tesirine-lpyl) is FDA approved for use in patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy (FDA.gov). |
|
Lorlatinib
|
Lorbrena |
PF-06463922|Lorviqua |
ALK Inhibitor
32
ROS1 Inhibitor
20
|
Lorbrena (lorlatinib) is a small molecule inhibitor of Alk and Ros1 fusion proteins, which may result in suppression of Alk and Ros1-mediated signaling thereby inhibiting cell growth and causing tumor regression (PMID: 26144315). Lorbrena (lorlatinib) is FDA approved for use in patients with ALK-positive non-small cell lung cancer (FDA.gov). |
|
Lurbinectedin
|
Zepzelca |
PM01183 |
Chemotherapy - Alkylating
18
|
Zepzelca (lurbinectedin) is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459). Zepzelca (lurbinectedin) is an FDA-approved chemotherapy agent (FDA.gov). |
|
Margetuximab-cmkb
|
Margenza |
MGAH22|MGAH-22 |
HER2 (ERBB2) Antibody
76
|
Margenza (margetuximab-cmkb) is a monoclonal antibody that binds ERBB2 (HER2) and induces antitumor response against ERBB2 (HER2)-expressing tumor cells (PMID: 22129105, PMID: 32653053). Margenza (margetuximab-cmkb) in combination with chemotherapy is FDA approved for use in patients with metastatic ERBB2 (HER2)-positive breast cancer who had received two or more prior anti-ERBB2 (HER2) therapies (FDA.gov). |
|
Melphalan
|
Alkeran |
|
Chemotherapy - Alkylating
18
|
Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity and is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov). |
|
Methotrexate
|
Abitrexate |
Amethopterin |
Chemotherapy - Antimetabolite
14
|
Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov). |
|
Mirvetuximab Soravtansine
|
Elahere |
IMGN853|M9346A-sulfo-SPDB-DM4|mirvetuximab soravtansine-gynx |
FOLR1-targeted Therapy
24
|
Elahere (mirvetuximab soravtansine) is an antibody-drug conjugate comprised of an antibody directed against FOLR1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506). Elahere (mirvetuximab soravtansine) is FDA approved for use in patients with FOLR1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatments (FDA.gov). |
|
Mitomycin gel
|
Jelmyto |
UGN-101|Mitogel|MP77-08 |
|
Jelmyto (mitomycin gel) is a prolonged release gel formulation of mitomycin that may have antitumor activity when applied in the upper urinary tract (PMID: 32670424). Jelmyto (mitomycin for pyelocalyceal solution) is FDA approved for use in patients with low-grade upper tract urothelial cancer (FDA.gov). |
|
Mosunetuzumab-axgb
|
Lunsumio |
RG7828|BTCT4465A|RO7030816|BTCT-4465A |
CD20 Antibody
24
CD3 Antibody
99
|
Lunsumio (mosunetuzumab-axgb) is a bispecific antibody targeting CD20 and CD3, which may result in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372). Lunsumio (mosunetuzumab-axgb) is FDA approved for use in adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy (FDA.gov). |
|
Nab-rapamycin
|
Fyarro |
ABI-009|nab-sirolimus |
mTORC1 Inhibitor
9
|
Fyarro (nab-rapamycin) is nanoparticle albumin-bound rapamycin and inhibitor of mTOR that has immunosuppressant and anti-tumor activities (PMID: 24089446). Fyarro (nab-rapamycin) is FDA approved for use in patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (FDA.gov). |
|
Nadofaragene firadenovec
|
Adstiladrin |
rAd-IFN|rAd-IFN-2b|Nadofaragene firadenove-vncg|SCH 721015|SCH721015|SCH-721015 |
|
Adstiladrin (nadofaragene firadenovec) is a recombinant adenovirus that encodes IFN alpha 2B, which may have potential antitumor activity (PMID: 11922775). Adstiladrin (nadofaragene firadenovec) is FDA approved for use in patients with high-risk BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ (FDA.gov). |
|
Naxitamab
|
Danyelza |
hu3F8 |
|
Danyelza (naxitamab) is an antibody that targets the ganglioside GD2, potentially resulting in increased anti-tumor immune response against GD2-expressing tumor cells (PMID: 22754766). Danyelza (naxitamab) is FDA approved for use in combination with GM-CSF in pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who achieved a partial response, minor response, or stable disease to prior therapy (FDA.gov). |
|
Niraparib and abiraterone acetate
|
Akeega |
CJNJ-67652000|CJNJ 67652000|CJNJ67652000 |
Hormone - Anti-androgens
54
PARP Inhibitor (Pan)
31
|
Akeega (niraparib and abiraterone acetate) is a combination of Zejula (niraparib) and Zytiga (abiraterone). Akeega (niraparib and abiraterone acetate) in combination with Adasone (prednisone) is FDA-approved for use in patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious BRCA1/2 mutations (FDA.gov). |
|
Nirogacestat
|
Ogsiveo |
PF-03084014|PF 03084014|PF03084014 |
Gamma secretase inhibitor
13
|
Ogsiveo (nirogacestat) is a small molecule that selectively binds to Gamma-secretase and inhibits its proteolytic activity on downstream targets including NOTCH receptor proteins, thus blocking NOTCH pathway activation in cancer (PMID: 28887726, PMID: 31211955). Ogsiveo (nirogacestat) is FDA-approved for use in patients with progressing desmoid tumors (FDA.gov). |
|
Nivolumab and relatlimab-rmbw
|
Opdualag |
BMS-986213 |
LAG3 Antibody
18
PD-L1/PD-1 antibody
121
|
Opdualag (nivolumab and relatlimab-rmbw) is a fixed-dose combination of Relatlimab (BMS-986016) and Opdivo (nivolumab), which may lead to enhanced anti-tumor immune response (PMID: 34986285). Opdualag (nivolumab and relatlimab-rmbw) is FDA approved for use in adult and pediatric patients of 12 years or older with unresectable or metastatic melanoma (FDA.gov). |
|
Nogapendekin alfa inbakicept
|
Anktiva |
N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803|ALT-803 |
|
Anktiva (nogapendekin alfa inbakicept) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557). Anktiva (nogapendekin alfa inbakicept) in combination with BCG is FDA approved for use in patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors (FDA.gov). |
|
Obecabtagene autoleucel
|
Aucatzyl |
Obe-cel|AUTO1|AUTO-1|AUTO 1 |
CD19 Immune Cell Therapy
62
|
Aucatzyl (obecabtagene autoleucel) comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, which potentially decreases tumor growth (J Clin Oncol 41, no. 16_suppl (June 01, 2023) 7000). Aucatzyl (obecabtagene autoleucel) is FDA-approved for use in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov). |
|
Octreotide acetate
|
Sandostatin Lar Depot |
SMS 201-995 |
|
Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, which may control the growth of neuroendocrine tumors (PMID: 26605828). Sandostatin Lar Depot (octreotide acetate) is FDA approved for symptom control in patients with carcinoid tumors and VIPomas (FDA.gov). |
|
Olutasidenib
|
Rezlidhia |
FT-2102 |
IDH1 Inhibitor
8
|
Rezlidhia (olutasidenib) targets IDH1 R132 mutations, leading to decreased 2HG production and potentially promoting differentiation and decreasing proliferation of IDH R132-mutant cancer cells (PMID: 31971798). Rezlidhia (olutasidenib) is FDA approved for use in adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation (FDA.gov). |
|
Omacetaxine mepesuccinate
|
Synribo |
homoharringtonine|CGX-635 |
|
Synribo (omacetaxine mepesuccinate) is a semisynthetic alkaloid that inhibits protein synthesis, resulting in increased apoptosis and cell-cycle arrest in tumor cells (PMID: 26935769, PMID: 24516334). Synribo (omacetaxine mepesuccinate) is FDA approved for use in patients with chronic myeloid leukemia (FDA.gov). |
|
Orlistat
|
Xenical |
(-)-Tetrahydrolipstatin |
|
Xenical (orlistat) is a fatty acid inhibitor that also demonstrates anti-tumor activity (PMID: 30667213). Xenical (orlistat) is FDA approved for weight management (FDA.gov). |
|
Oxaliplatin
|
Eloxatin |
Diaminocyclohexane Oxalatoplatinum |
Chemotherapy - Platinum
7
|
Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
|
Pacritinib
|
Vonjo |
SB1518|SB-1518|SB 1518 |
FLT3 Inhibitor
69
JAK2 Inhibitor - ATP competitive
15
|
Vonjo (pacritinib) is an inhibitor of JAK2 and FLT3, with activity against JAK2 V617F and FLT3 ITD, which potentially increases tumor cell apoptosis, induces cell cycle arrest, and decreases tumor growth (PMID: 22829080, PMID: 21691275). Vonjo (pacritinib) is FDA approved for use in patients with primary or secondary myelofibrosis (FDA.gov). |
|
Pegylated liposomal doxorubicin
|
Doxil |
ATI-0918|CAELYX|liposomal doxorubicin |
Chemotherapy - Anthracycline
13
|
Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
|
Pexidartinib
|
Turalio |
PLX3397|CML-261 |
CSF1R Inhibitor
28
FLT3 Inhibitor
69
KIT Inhibitor
57
|
Turalio (pexidartinib) inhibits multiple receptor tyrosine kinases, including KIT, CSF1R, FLT3, and FLT3/ITD, which may inhibit growth in cancer cells (PMID: 22294205, PMID: 25993548, PMID: 25847190). Turalio (pexidartinib) is FDA approved for use in patients with symptomatic tenosynovial giant cell tumor (FDA.gov). |
|
Pirtobrutinib
|
Jaypirca |
LOXO-305|LOXO 305|LOXO305|RXC005|REDX08608 |
BTK inhibitor
37
|
Jaypirca (pirtobrutinib) selectively inhibits the activation of BTK, which may result in decreased tumor growth (PMID: 32170458, PMID: 33676628). Jaypirca (pirtobrutinib) is FDA approved for use in patients with relapsed or refractory mantle cell lymphoma who had received at least two lines of systemic therapy, and in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy (FDA.gov). |
|
Pomalidomide
|
Pomalyst |
CC-4047 |
|
Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov). |
|
Pralsetinib
|
Gavreto |
BLU667|BLU-667 |
RET Inhibitor
53
|
Gavreto (pralsetinib) is a small molecule inhibitor that selectively targets activated Ret, which may result in antitumor activity including inhibition of tumor growth and tumor regression (PMID: 29657135). Gavreto (pralsetinib) is FDA approved for use in patients with metastatic RET fusion-positive non-small cell lung cancer, in adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer, and in adult and pediatric patients 12 years of age and older with RET fusion-positive thyroid cancer who are radioactive iodine-refractory (FDA.gov). |
|
Quizartinib
|
Vanflyta |
AC220 |
FLT3 Inhibitor
69
|
Vanflyta (quizartinib) is a small molecule that selectively inhibits FLT3, which may induce apoptosis and inhibit tumor growth (PMID: 19654408, PMID: 23497317). Vanflyta (quizartinib) is FDA-approved for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, in patients with newly diagnosed acute myeloid leukemia harboring FLT3 ITD mutations (FDA.gov). |
|
Repotrectinib
|
Augtyro |
TPX-0005 |
ALK Inhibitor
32
JAK2 Inhibitor
19
ROS1 Inhibitor
20
SRC Inhibitor
31
Trk Receptor Inhibitor (Pan)
32
|
Augtyro (repotrectinib) is a multi-kinase inhibitor that demonstrates strong activity against Ros1, Ntrk1/2/3, and Alk, and also inhibits Jak2 and Src family kinases, resulting in tumor cell death (PMID: 30093503, PMID: 32269053). Augtyro (repotrectinib) is FDA-approved for use in patients with advanced or metastatic ROS1 fusion-positive non-small cell lung cancer, and in adult and pediatric patients 12 years or older with advanced solid tumors harboring NTRK fusions (FDA.gov). |
|
Retifanlimab
|
Zynyz |
MGA 012|INCMGA00012|MGA012|retifanlimab-dlwr |
Immune Checkpoint Inhibitor
149
PD-L1/PD-1 antibody
121
|
Zynyz (retifanlimab) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). Zynyz (retifanlimab) is FDA approved for use in adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (FDA.gov). |
|
Revumenib
|
Revuforj |
SNDX5613|SNDX 5613|SNDX-5613 |
MEN1-KMT2A Inhibitor
8
|
Revuforj (revumenib) inhibits the interaction between Menin and KMT2A (MLL), potentially resulting in antitumor activity and decreased proliferation of tumor cells with KMT2A (MLL) rearrangements or NPM1 mutations (PMID: 36922593, PMID: 36922589). Revuforj (revumenib) is FDA-approved for use in adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia harboring KMT2A translocation (FDA.gov). |
|
Ripretinib
|
Qinlock |
DCC-2618|DCC2618 |
KIT Inhibitor
57
PDGFR-alpha Inhibitor
9
|
Qinlock (ripretinib) is a dual inhibitor of KIT and PDGFRa, resulting in growth inhibition and anti-tumor effects (PMID: 29439183, PMID: 31085175, PMID: 31201392). Qinlock (ripretinib) is FDA approved for use in patients with advanced gastrointestinal stromal tumor who received 3 or more prior kinase inhibitor therapies (FDA.gov) |
|
Sacituzumab govitecan-hziy
|
Trodelvy |
IMMU-132|Sactizumab|Sacituzumab govitecan |
TROP2 Antibody
13
|
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more prior therapies, in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies, and in patients with locally advanced or metastatic urothelial cancer who received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor (FDA.gov). |
|
Siltuximab
|
Sylvant |
CNTO 328|CNTO328 |
|
Sylvant (siltuxmab) is an anti-IL-6 chimeric monoclonal antibody, which inhibits IL6 signaling and may lead to decreased tumor cell growth (PMID: 26170629, PMID: 26744529). Sylvant (siltuximab) is FDA approved for patients with multicentric Castleman's disease who do not have HIV or HHV-8 (FDA.gov). |
|
Sipuleucel-T
|
Provenge |
APC 8015 |
|
Provenge (sipuleucel-T) is composed of autologous dendritic cells exposed to a PAP-GCSF fusion protein (PA2024), which stimulates a cytotoxic immune response towards PAP-expressing tumor cells (PMID: 25565923, PMID: 25708576). Provenge (sipuleucel-T) is FDA-approved for use in patients with metastatic castration-resistant prostate cancer (FDA.gov). |
|
Sotorasib
|
Lumakras |
AMG 510|AMG510|AMG-510|Lumykras |
KRAS G12C inhibitor
34
|
Lumakras (sotorasib) is small molecule inhibitor that selectively targets KRAS G12C and inhibits downstream signaling, which may lead to growth inhibition of tumors harboring KRAS G12C (PMID: 31666701). Lumakras (sotorasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov). |
|
Sulindac
|
Clinoril |
MK-231 |
|
Clinoril (sulindac) is a non-selective COX1-2 inhibitor, FDA approved as an anti-inflammatory agent (FDA.gov), and Clinoril (sulindac) also reduces intestinal tumor burden (PMID: 19755659). |
|
Tafasitamab-cxix
|
Monjuvi |
MOR00208|XmAb5574|MOR-208|MOR208|Tafasitamab |
CD19 Antibody
21
|
Monjuvi (tafasitamab-cxix) is an CD19-targeted antibody with an engineered Fc region, which may result in an increased antibody-dependent cell-mediated cytotoxicity response against CD19-expressing tumor cells (PMID: 23277329, PMID: 32511983). Monjuvi (tafasitamab-cxix) is FDA approved for use in combination with Revlimid (lenalidomide) in patients with relapsed or refractory diffuse large B cell lymphoma (FDA.gov). |
|
Talquetamab-tgvs
|
Talvey |
JNJ64407564|JNJ 64407564|JNJ-64407564 |
CD3 Antibody
99
|
Talvey (talquetamab-tgvs) is a bispecific antibody that targets CD3 and GPRC5D, potentially resulting in increased immune response against GPRC5D-expressing tumor cells (PMID: 32040549). Talvey (talquetamab-tgvs) is FDA-approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov). |
|
Tarlatamab
|
Imdelltra |
AMG 757|AMG757|AMG-757|tarlatamab-dlle |
CD3 Antibody
99
DLL3 Antibody
6
|
Imdelltra (tarlatamab) is a bispecific antibody that targets CD3 on T-cells and delta-like protein 3 (DLL3) expressed by tumor cells, which may lead to cytotoxic killing of Dll3-expressing tumor cells (PMID: 31215500). Imdelltra (tarlatamab) is FDA-approved for use in patients with extensive stage small cell lung cancer who progressed on or after platinum-based chemotherapy (FDA.gov). |
|
Teclistamab
|
Tecvayli |
JNJ-64007957|BCMAxCD3|JNJ 64007957|JNJ64007957 |
CD3 Antibody
99
TNFRSF17 Antibody
20
|
Tecvayli (teclistamab) is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668). Tecvayli (teclistamab) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov). |
|
Tepotinib
|
Tepmetko |
EMD1214063|EMD-1214063|EMD 1214063|MSC2156119|MSC-2156119|MSC2156119J |
MET Inhibitor
59
|
Tepmetko (tepotinib) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein (PMID: 32328660). Tepmetko (tepotinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
|
Thalidomide
|
Thalomid |
N-Phthalimidoglutamic acid imide |
|
Thalomid (thalidomide) is a a racaemic glutamic acid analogue that has anti-inflammatory, anti-angiogenic, immunosuppressive, and anti-tumor activities (PMID: 15172781). Thalomid (thalidomide) is approved for use in combination with dexamethasone for patients with newly diagnosed multiple myeloma (FDA.gov). |
|
Tisagenlecleucel
|
Kymriah |
CTL019 |
CD19 Immune Cell Therapy
62
|
Kymriah (tisagenlecleucel) is a preparation of autologous T-lymphocytes engineered to express chimeric antigen receptors targeting CD19-positive cells, resulting in anti-tumor immune response (J Clin Oncol 35, 2017 (suppl; abstr 10523)). Kymriah (tisagenlecleucel) is FDA approved for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia, adult patient with relapsed or refractory large B-cell lymphoma, and adult patients with relapsed or refractory follicular lymphoma (FDA.gov). |
|
Tislelizumab
|
Tevimbra |
BGB-A317|tislelizumab-jsgr |
Immune Checkpoint Inhibitor
149
PD-L1/PD-1 antibody
121
|
Tevimbra (tislelizumab) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). Tevimbra (tislelizumab) is FDA-approved for use in patients with unresectable or metastatic esophageal squamous cell carcinoma (FDA.gov). |
|
Tisotumab vedotin-tftv
|
Tivdak |
HuMax-TF-ADC|TF-011-MMAE |
|
Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells overexpressing tissue factor (PMID: 24371232, PMID: 31796521). Tivdak (tisotumab vedotin-tftv) is FDA approved fro use in patients with with recurrent or metastatic cervical cancer (FDA.gov). |
|
Tivozanib
|
Fotivda |
AV-951|AV951|KIL-8951|KRN 951|KRN-951 |
VEGFR Inhibitor (Pan)
36
|
Fotivda (tivozanib) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831, PMID: 31810797, PMID: 32547647). Fotivda(tivozanib) is FDA approved for use in adult patients with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies (FDA.gov). |
|
Tocilizumab
|
Actemra |
Atlizumab |
|
Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov). |
|
Tofacitinib
|
Xeljanz |
Tasocitinib|CP-690550|CP-690,550 |
JAK Inhibitor (Pan) - ATP competitive
3
|
Xeljanz (tofacitinib) is a pan-JAK inhibitor, which decreases downstream signaling and potentially leads to reduced tumor cell growth (PMID: 26300391, PMID: 21106989). Xeljanz (tofacitinib) is FDA approved for rheumatoid arthritis (FDA.gov). |
|
Toripalimab-tpzi
|
Loqtorz |
Toripalimab|JS001|JS-001|TAB001 |
Immune Checkpoint Inhibitor
149
PD-L1/PD-1 antibody
121
|
Loqtorz (toripalimab-tpzi) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; PMID: 32277740, PMID: 32406293, PMID: 32321714). Loqtorz (toripalimab-tpzi) in combination with cisplatin and gemcitabine is FDA-approved for use in adult patients with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (FDA.gov). |
|
Tovorafenib
|
Ojemda |
BIIB-024|TAK-580|MLN-2480|TAK580|DAY101|MLN2480 |
RAF Inhibitor (Pan)
28
|
Ojemda (tovorafenib) is an inhibitor of pan-Raf kinases, which interrupts RAF/MEK/ERK signal transduction pathways to inhibit tumor cell growth (PMID: 28082416, PMID: 30622172). Ojemda (tovorafenib) is FDA approved for use in patients 6 months or older with relapsed or refractory pediatric low grade glioma harboring BRAF fusion or rearrangement or BRAF V600 mutation (FDA.gov). |
|
Trametinib
|
Mekinist |
GSK1120212 |
MEK inhibitor (Pan)
26
MEK1 Inhibitor
26
MEK2 Inhibitor
24
|
Mekinist (trametinib) inhibits MEK 1 and 2, which potentially leads to reduced tumor cell proliferation (PMID: 27956260). Mekinist (trametinib) is FDA approved for melanoma patients harboring BRAF V600E or BRAF V600K mutations, and in combination with Tafinlar (dabrafenib) for BRAF V600E/K-mutant melanoma, BRAF V600E- mutant non-small cell lung cancer, BRAF V600E-mutant anaplastic thyroid cancer, for adult and pediatric patients of 6 years or older with unresectable or metastatic solid tumors harboring BRAF V600E, and for pediatric patients of 1 year or older with low-grade glioma harboring BRAF V600E (FDA.gov). |
|
Trastuzumab deruxtecan
|
Enhertu |
DS-8201|DS8201a|T-DXd|DS-8201|fam-trastuzumab deruxtecan-nxki|DS-8201a |
HER2 (ERBB2) Antibody
76
HER2 (ERBB2) Antibody-Drug Conjugate
31
|
Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate (ADC) comprising an anti-ERBB2 (HER2) antibody linked to a derivative of the topoisomerase inhibitor DX-8951, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of tumors, including tumors with low ERBB2 (HER2) expression (PMID: 27026201). Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved for use in patients with ERBB2 (HER2)-positive breast cancer who have received two or more anti-HER2 therapies previously, in patients with ERBB2 (HER2)-low (IHC 1+ or IHC 2+/ISH -) breast cancer received prior chemotherapy, in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received prior trastuzumab-based therapy, in patients with non-small cell lung cancer harboring ERBB2 (HER2) activating mutations who have received prior systemic therapy, and in patients with ERBB2 (HER2)-positive (IHC 3+) solid tumors who have received prior systemic therapy (FDA.gov). |
|
Tremelimumab
|
Imjudo |
CP-675,206|Ticilimumab|CP-675206 |
CTLA4 Antibody
31
Immune Checkpoint Inhibitor
149
|
Imjudo (tremelimumab) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937). Imjudo (tremelimumab) is FDA approved for use in combination with Imfinzi (durvalumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with Imfinzi (durvalumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations (FDA.gov). |
|
Tretinoin
|
Vesanoid |
Aberel|Aknoten|Avita|Renova|Retin-A|all-trans retinoic acid|Vitamin A Acid|ATRA |
|
Vesanoid (tretinoin) is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially inducing cell differentiation and subsequently, apoptosis (PMID: 11704842). Vesanoid (tretinoin) is FDA approved for patients with acute promyelocytic leukemia harboring PML-RARA (FDA.gov). |
|
Umbralisib
|
Ukoniq |
RP5264|TGR-1202 |
PIK3CD inhibitor
27
|
Ukoniq (umbralisib) is a selective inhibitor of PIK3CD, which prevents Akt phosphorylation and induces cytotoxicity (J Clin Oncol 32:5s, 2014 (suppl; abstr 2513), PMID: 30709431). Ukoniq (umbralisib) is FDA approved for use in adult patients with relapsed or refractory marginal zone lymphoma with one or more prior anti-CD20-based therapy, and in adult patients with relapsed or refractory follicular lymphoma who have three or more prior lines of therapy (FDA.gov). |
|
Vincristine sulfate liposome
|
Marqibo |
VSL |
|
Marqibo (vincristine sulfate liposome) is a liposomal formulation of vincristine with improved bioavailability (PMID: 23212117). Marqibo (vincristine sulfate liposome) is FDA-approved for Philadelphia chromosome (BCR-ABL1)-negative acute lymphoblastic leukemia (FDA.gov). |
|
Vinorelbine
|
Navelbine |
Vinorelbin |
Antimicrotubule Agent
14
|
Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov). |
|
Vorasidenib
|
Voranigo |
AG-881|AG881 |
IDH Inhibitor (Pan)
3
|
Voranigo (vorasidenib) inhibits both mutant IDH1 and IDH2, thereby inhibiting cell proliferation in tumors expressing mutant IDH (PMID: 27292784, PMID: 32071674). Voranigo (vorasidenib) is FDA-approved for use in adult and pediatric patients 12 years and older with IDH-mutant grade 2 astrocytoma or oligodendroglioma following surgery (FDA.gov) |
|
Vorinostat
|
Zolinza |
SAHA|L-001079038|MSK390 |
HDAC Inhibitor
45
|
Zolinza (vorinostat) inhibits HDAC activity, resulting in cell-cycle arrest, decreased proliferation, and increased differentiation of tumor cells (PMID: 9501205, PMID: 11731433, PMID: 11016644). Zolinza (vorinostat) is FDA approved for use in cutaneous T-cell lymphoma (FDA.gov). |
|
Zanubrutinib
|
Brukinsa |
BGB-3111 |
BTK inhibitor
37
|
Brukinsa (zanubrutinib) inhibits Bruton tyrosine kinase (BTK), leading to decreased B-cell activation and reduced growth of BTK over-expressing cells (PMID: 31378456). Brukinsa (zanubrutinib) is FDA approved for use in patients with mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) (FDA.gov). |
|
Zolbetuximab
|
Vyloy |
IMAB362|Claudiximab |
CLDN18.2 Antibody
19
|
Vyloy (zolbetuximab) is a monoclonal antibody that binds to the tight junction molecule CLDN18.2, thereby blocking proliferation of tumor cells (PMID: 23900716, PMID: 26811601, PMID: 31240302). Vyloy (zolbetuximab) is FDA-approved for use in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with CLDN18.2-positive, locally advanced unresectable or metastatic ERBB2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma (FDA.gov). |
|
afamitresgene autoleucel
|
Tecelra |
MAGE-A4 SPEAR T cells|MAGE-A4C1032T|ADP-A2M4 cells|afami-cel |
|
Tecelra (afamitresgene autoleucel) are autologous T-cells that are modified to express a T-cell receptor that recognizes the human melanoma antigen 4 (MAGE-A4) peptide region from 230-239, which potentially inhibits growth of MAGE-A4-expressing tumor cells (PMID: 32002290). Tecelra (afamitresgene autoleucel) is FDA-approved for use in patients with MAGE-A4-positive unresectable or metastatic synovial sarcoma who have received prior chemotherapy, and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive (FDA.gov). |
|
axicabtagene ciloleucel
|
Yescarta |
KTE-C19 CAR|KTE-C19 |
CD19 Immune Cell Therapy
62
|
Yescarta (axicabtagene ciloleucel) is an immunotherapy consisted of peripheral T-lymphocytes engineered to express a chimeric antigen receptor targeting CD19, CD28 and CD3zeta, resulting in immunostimulating and antineoplastic activities (PMID: 32401634). Yescarta (axicabtagene ciloleucel) is FDA approved for adult patients with large B-cell lymphoma who is refractory or relapsed on first-line chemoimmunotherapy or have received two or more lines of therapies, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, and for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of therapies, but is not indicated for patients with primary central nervous system lymphoma (FDA.gov). |
|
lutetium Lu 177 vipivotide tetraxetan
|
Pluvicto |
Lu177-PSMA-617|Vipivotide tetraxetan Lu-177 |
|
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioconjugate comprising a prostate-specific membrane antigen (PSMA) inhibitor radiolabeled with Lu177, which targets PSMA expressing cells, potentially resulting in decreased tumor growth (PMID: 25883127, PMID: 26795286, PMID: 32760622). Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is FDA approved for use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received androgen receptor (AR) pathway inhibition and taxane-based chemotherapy (FDA.gov). |